P69 Baseline characteristics of patients with physician-diagnosed hidradenitis suppurativa: results from a retrospective observational study using data from the Clinical Practice Research Datalink database

Abstract Hidradenitis suppurativa (HS) is a difficult-to-treat, painful, chronic inflammatory skin disorder characterized by nodules, abscesses and tunnels. Delay in diagnosis increases disease severity overall burden. In England, HS associated with high healthcare resource use, an estimated prevalence of 1.2% the general UK population (Ingram JR, Jenkins-Jones S, Knipe DW et al. Population-based Clinical Practice Research Datalink study using algorithm modelling to identify true burden hidradenitis suppurativa. Br J Dermatol 2018; 178:917–24). Improved understanding patient profiles England will help optimize care treatment outcomes. This aimed characterize profiles, journey, pathways outcomes patients data from database. Here, we present baseline characteristics this Overall, 39 860 physician-diagnosed were identified 1 January 2009 31 March 2021. The mean (SD) age at was 34.49 (13.07) years, majority female (73.8%). Twenty-seven per cent White, 7.5% Asian, 5.0% Black 27.9% mixed race, while 2.1% other races race unknown for 30.7%. 44.6% current smokers 12.7% ex-smokers. Depression (31.7%), anxiety (21.5%) acne (20.6%) most commonly reported comorbidities related HS. Chronic pulmonary 26.2% patients; may, part, be attributed relatively rates smoking population. frequently prescribed medications prior pain medication, especially ‘non-opioid’ analgesics (21.8%) opioids (19.8%); oral antibiotics, particularly tetracyclines (15.7%); combined contraceptive pills (7.2%) metformin (4.8%). Only few (< 0.05%) received biologic their conditions. various comorbidities, including psychiatric, metabolic, cardiovascular, gynaecological treatments, observed real-world suggest that optimal management should involve multidisciplinary approach improve